Artelo Biosciences, Inc.
ARTL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.00 | 0.09 |
| FCF Yield | -6.75% | -9.27% | -74.76% | -9.10% |
| EV / EBITDA | -2.04 | -6.97 | -0.31 | -15.41 |
| Quality | ||||
| ROIC | 596.59% | -318.47% | -128.74% | -18.46% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.12 | 0.13 | 0.67 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 67.81% | 37.79% | -30.04% | -95,585.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.38 | 0.27 | 0.59 | 3.75 |
| Interest Coverage | -43.75 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |